New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:29 EDTIDIXIdenix reports interim data from phase II trial of samatasvir
Idenix Pharmaceuticals announced interim data from the company's ongoing phase II 12-week HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral HCV combination regimen of samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, and simeprevir, a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, plus ribavirin. The combination regimen was well-tolerated in the study. In the treatment-na´ve, non-cirrhotic, genotype 1b or 4 HCV-infected patients receiving 50 mg of samatasvir and 150 mg of simeprevir plus ribavirin, 85% remained undetectable for HCV RNA four weeks after completing therapy. The 50 mg dose of samatasvir is the selected dose in the ongoing 3-DAA HELIX-2 clinical trial. The HELIX-1 study results are expected to be presented at a scientific meeting in 2014.
News For IDIX From The Last 14 Days
Check below for free stories on IDIX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
11:12 EDTIDIXOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use